Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 5/20 | 0.43 |
| ▸ | F11 | P03951 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120621 | 0.85 | PRCP (0.47) | PRCP | |
| SCHEMBL888956 | 0.84 | PRCP (0.44) | PRCP | |
| SCHEMBL12772551 | 0.81 | CYP3A4 (0.48) | CYP3A4CYP2C9 | |
| SCHEMBL11924847 | 0.81 | PRCP (0.49) | PRCPCYP3A4CYP2C9 | |
| SCHEMBL12565507 | 0.79 | PRCP (0.47) | PRCPCYP3A4CYP2C9 | |
| SCHEMBL10092494 | 0.78 | CYP3A4 (0.58) | CYP3A4CYP2C9 | |
| SCHEMBL18775081 | 0.77 | PRCP (0.44) | PRCP | |
| SCHEMBL15887523 | 0.77 | PRCP (0.49) | PRCP | |
| SCHEMBL12771334 | 0.77 | CYP3A4 (0.51) | CYP3A4CYP2C9 | |
| SCHEMBL12247850 | 0.75 | CYP3A4 (0.59) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815928-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | PRCP 289/4885F2 2572/4885F11 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.